In this study, we assessed mutations in patients with thyroid cancer across the spectrum of tumor dedifferentiation, and genomic and transcriptomic profiles of matched pre- and post-BRAF inhibitor treated thyroid tumors harboring BRAF V600E mutations, including a number of cases that dedifferentiated during the course of this study. Here, BRAF is linked to neoplasm.